FDA Adopts Super Intelligence (SI) Terminology Across Agency Communications

FDA Adopts Super Intelligence (SI) Terminology Across Agency Communications

REGULATORY UPDATE

The U.S. Food and Drug Administration (FDA) announced that beginning November 16, 2026, it will use the terms Super Intelligence (SI) and Super Intelligence Systems in newly issued public-facing documents and communications, replacing references to Artificial Intelligence (AI) where applicable.

This change follows Executive Order 14434 – Inaugurating the Era of Super Intelligence, issued by the White House on September 29, 2026.

WHAT IS CHANGING?

Previous Terminology New Terminology
Artificial Intelligence (AI) Super Intelligence (SI)
AI Systems Super Intelligence Systems
Federal agencies are directed to use the updated terminology in:
  • Official correspondence
  • Public communications
  • Agency websites
  • Reports and policy documents
  • Non-statutory guidance materials

WHAT IS NOT CHANGING?

The FDA has clarified that this update:
  • Does not create new regulatory requirements
  • Does not affect current FDA regulations or guidance documents
  • Does not require changes to product names, labeling, or submissions
  • Does not alter existing compliance expectations for regulated industry
Key FDA Message: The Executive Order does not create new obligations for sponsors, applicants, manufacturers, or other entities regulated by FDA.

IMPACT ON INDUSTRY

Companies may begin seeing the term Super Intelligence (SI) appear in:
  • FDA guidance documents
  • Regulatory communications
  • Scientific publications
  • Digital health discussions
  • Manufacturing innovation programs
  • Public workshops and presentations

Potentially affected sectors include:

  • Pharmaceutical Development
  • Biotechnology
  • Medical Devices & SaMD
  • Advanced Manufacturing
  • Clinical Trial Analytics
  • Pharmacovigilance & Quality Systems

RECOMMENDED ACTIONS

Regulatory Affairs Teams

  • Monitor future FDA communications for SI terminology.
  • Update regulatory intelligence monitoring programs.
  • Maintain current submission practices unless otherwise specified by FDA.

Quality & Compliance Teams

  • Educate stakeholders regarding the terminology shift.
  • Continue following existing FDA regulations and guidance documents as written.

Technology & Innovation Teams

  • Expect future references to SI in FDA communications involving AI-enabled products and technologies.

MASUU REGULATORY INSIGHT

While this announcement primarily represents a Federal terminology change, it reflects the increasing strategic focus on advanced computational technologies across healthcare, life sciences, manufacturing, and regulatory science.

Masuu Global developing AI-enabled software, predictive analytics platforms, digital health solutions, automated manufacturing systems, or data-driven quality tools should remain attentive to future FDA policy developments that may further shape the regulatory landscape.

KEY TAKEAWAY

  • AI → SI in FDA Communications
  • No New Regulatory Requirements
  • Existing FDA Regulations and Guidance Remain Unchanged
  • Industry Should Monitor Future FDA Communications for Continued Implementation

References:

  1. https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/
  2. https://www.fda.gov/science-research/fda-and-super-intelligence/fdas-use-super-intelligence-and-si-under-executive-order-14434
Book a Demo